|
Enerpac Tool Group Corp. (EPAC): BCG Matrix [Dec-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Enerpac Tool Group Corp. (EPAC) Bundle
You need a clear-eyed view of Enerpac Tool Group Corp. (EPAC) right now, so I've mapped their business units using the late 2025 BCG Matrix. Honestly, the picture is mixed: we have Stars like the E-commerce channel posting a massive 32% growth, feeding the Cash Cows-your core hydraulic tools that delivered $479 million in sales and a 24.9% adjusted EBITDA margin. Still, we can't ignore the Dogs, like the IT&S Service revenue's 7% Q4 decline, or the big Question Marks surrounding the DTA acquisition integration and the overall IT&S segment's low 0.5% organic growth. Keep reading to see precisely which segments demand your immediate capital focus.
Background of Enerpac Tool Group Corp. (EPAC)
You're looking for the lay of the land on Enerpac Tool Group Corp. (EPAC) as of late 2025, so let's get straight to the numbers from their recently closed fiscal year. Enerpac Tool Group Corp. is a global leader in providing high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. For the fiscal year ended August 31, 2025, the company posted record net sales of $617 million, which was a 4.6% increase year-over-year. Honestly, that revenue figure is the highest since the brand was relaunched in 2019.
Digging into that growth, the organic growth rate for fiscal 2025 was relatively modest at just 1.0%. This tells us a good chunk of the top-line expansion came from strategic moves, specifically the acquisition of DTA, which contributed to the overall sales lift. Profitability remained strong; adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) hit $154 million, representing a 4% increase, with the adjusted EBITDA margin holding steady at 24.9%. You can see the focus on efficiency, as free cash flow jumped 31% to $92 million in fiscal 2025.
The business is primarily structured around its Industrial Tools & Services (IT&S) segment, which offers branded tools like hydraulic cylinders, pumps, torque wrenches, and services across critical sectors like refinery/petrochemical, power generation, and infrastructure. However, the smaller 'Other' segment, which includes Cortland Biomedical, showed some serious muscle, posting the strongest growth at 14.8% for the year. Geographically, the company's sales are fairly spread out, with the United States accounting for 37% of net sales, followed by Europe at 28%, and the Middle East making up 13%.
From a balance sheet perspective, Enerpac Tool Group Corp. is in a very strong position, which is important given the uncertain macro environment. As of August 31, 2025, their net debt to adjusted EBITDA ratio was extremely low at just 0.3x. This financial flexibility allowed the company to return capital to shareholders, with the board authorizing a new $200 million share repurchase program in October 2025. They definitely used that strong cash flow to support investors, which is a key theme heading into the next year.
Enerpac Tool Group Corp. (EPAC) - BCG Matrix: Stars
Stars are business units operating in high-growth markets where Enerpac Tool Group Corp. (EPAC) maintains a high relative market share. These units require substantial investment to maintain their leadership position and fuel further expansion, often resulting in cash flow that is reinvested back into the unit.
The Cortland Biomedical segment clearly exemplifies a Star within the Enerpac Tool Group Corp. portfolio, demonstrating exceptional top-line momentum in fiscal 2025. This segment's performance significantly outpaced the overall company organic growth of 1.0% for the full fiscal year 2025. The growth trajectory suggests this area is in a high-growth market where Enerpac Tool Group Corp. has established a strong competitive foothold.
Key statistical indicators supporting the Star classification for relevant areas of the business include:
- Cortland Biomedical segment organic growth for fiscal 2025: 14.8%.
- Asia region net sales as a percentage of total fiscal 2025 net sales: 11%.
- Overall company fiscal 2025 net sales: $617 million.
- Overall company fiscal 2025 adjusted EBITDA: $153.6 million.
The focus on expanding digital reach and customer engagement, particularly in emerging areas, is a strategic investment supporting potential future Cash Cows. The company continues to emphasize customer-driven innovation, which is evidenced by ongoing efforts in this area.
The Asia-Pacific (APAC) region is a key growth market where Enerpac Tool Group Corp. is actively investing to solidify its position. In fiscal 2025, the Asia region accounted for 11% of the total net sales, and the IT&S segment experienced strong performance driven by the APAC region.
The investment strategy for Stars is evident in the company's commitment to product pipeline development. While the exact count for new introductions in fiscal 2025 is not explicitly stated as 5, the commitment to customer-focused innovation and expanding the digital ecosystem is a clear investment in these high-growth areas.
| Metric | Value/Data Point | Fiscal Year |
| Cortland Biomedical Organic Growth | 14.8% | 2025 |
| Asia Region Net Sales Share | 11% | 2025 |
| Total Net Sales | $617 million | 2025 |
| Overall Organic Growth | 1.0% | 2025 |
Enerpac Tool Group Corp. (EPAC) - BCG Matrix: Cash Cows
You're looking at the bedrock of Enerpac Tool Group Corp.'s financial strength, the Cash Cows. These are the established businesses where market share is high, growth is mature, and the primary job is to generate excess cash to fund other parts of the portfolio. For Enerpac Tool Group Corp., the Industrial Tools & Services (IT&S) segment clearly fits this profile.
The Industrial Tools & Services (IT&S) Product Sales segment is the core engine, bringing in $479 million in revenue for fiscal 2025. This business unit is a global leader in core high-pressure hydraulic tools, which is exactly what you expect from a Cash Cow-a dominant position in a mature space. This dominance translates directly to profitability; the segment delivered a high adjusted EBITDA margin of 24.9% for the full fiscal year 2025. That margin is the key indicator of efficiency and pricing power in a stable market. Honestly, that kind of margin on core industrial products is what keeps the lights on and funds the future.
The performance across geographies supports this stability. While some areas faced headwinds, the Americas region demonstrated strong performance and stable demand throughout fiscal 2025, providing a reliable base for the IT&S segment. This contrasts with the mid single-digit declines seen in the EMEA region, showing where the stability is concentrated.
The ultimate output of a Cash Cow is cash, and Enerpac Tool Group Corp. delivered. The company achieved high free cash flow generation, reaching $92 million in fiscal 2025. This figure is what allows Enerpac Tool Group Corp. to service debt, fund share repurchases, and support other business units. Here's the quick math: Cash from operations was $111.3 million, and capital expenditures were $19.3 million for the year, resulting in that strong free cash flow figure. What this estimate hides is the ongoing investment in infrastructure, like the new global headquarters, which is a necessary support investment to maintain efficiency.
You can see the financial weight of this segment in the overall fiscal 2025 results:
| Metric | Value (Fiscal 2025) |
| Total Net Sales | $617 million |
| IT&S Product Sales | $479 million |
| Adjusted EBITDA | $153.6 million |
| Adjusted EBITDA Margin | 24.9% |
| Net Cash from Operating Activities | $111.3 million |
| Capital Expenditures | $19.3 million |
| Free Cash Flow | $92 million |
The Cash Cow status is reinforced by the capital allocation decisions made possible by this strong cash generation:
- Returned $69 million to shareholders through share repurchases in fiscal 2025.
- Board authorized a new $200 million share repurchase program in October 2025.
- Net debt to adjusted EBITDA ratio stood at a very low 0.3x as of August 31, 2025.
- The business unit's high profitability allows for low promotion and placement investments relative to revenue.
The strategy here is clear: maintain the current level of productivity and milk the gains passively, while ensuring investments in infrastructure, like the new headquarters, improve efficiency further. Finance: draft 13-week cash view by Friday.
Enerpac Tool Group Corp. (EPAC) - BCG Matrix: Dogs
The Dogs quadrant in the Boston Consulting Group (BCG) Matrix represents business units or product lines operating in low-growth markets with a low relative market share. These areas typically consume management time and capital without generating significant returns, making them prime candidates for divestiture or minimization. For Enerpac Tool Group Corp. (EPAC), several indicators point toward certain areas fitting this profile as of fiscal year 2025.
The overall performance for the full fiscal year 2025 showed a modest organic growth rate of 1.0% across continuing operations, which suggests that a significant portion of the business is operating in low-growth or stagnant markets, a hallmark of the Dog category. This low overall growth was achieved while the company saw reported net sales increase by 4.6% year-over-year to $617 million, largely due to acquisitions like DTA and favorable foreign currency impacts, masking underlying weakness in organic performance. You see, when organic growth is that low, it means the core business isn't expanding on its own merits.
Underperforming Segments and Regions
Specific data points from the fourth quarter of fiscal 2025 highlight areas that align with the Dog characteristics. The IT&S Service revenue, which is a key component of the service offering, experienced an organic decline of 7.4% in the fourth quarter of fiscal 2025. Service revenue declining at this rate in a single quarter is a major red flag for a business unit that should ideally be a stable Cash Cow or a growing Star.
Geographically, the Europe, Middle East, and Africa (EMEA) region showed significant weakness. For the Industrial Tools & Services (IT&S) segment, EMEA experienced mid single-digit declines in regional sales. To put that into perspective, EMEA represents 40% of IT&S regional sales, meaning weakness in this large block directly drags down overall segment performance. The consolidated organic sales for the entire company actually decreased by 1.8% in Q4 2025, further underscoring regional and product line struggles.
The IT&S segment itself, the core of the legacy business, saw its organic sales decline by 2.2% in the fourth quarter of fiscal 2025. This contrasts sharply with the growth seen in the Other segment, which includes Cortland Biomedical, growing at 10.4% organically in Q4 2025. This divergence suggests that the traditional product lines within IT&S are indeed the laggards.
Here's a quick look at the key negative statistical indicators from the fourth quarter of fiscal 2025:
| Metric | Value | Period |
|---|---|---|
| Consolidated Organic Sales Change | -1.8% | Q4 FY2025 |
| IT&S Segment Organic Sales Change | -2.2% | Q4 FY2025 |
| IT&S Service Revenue Organic Decline | -7.4% | Q4 FY2025 |
| EMEA Share of IT&S Regional Sales | 40% | FY2025 |
Low Growth Product Lines
The overall full-year organic growth rate of 1.0% suggests that many legacy product lines are barely growing, if at all, when factoring in the higher growth from newer areas like Cortland Biomedical. Products sold into the soft industrial sector are specifically flagged as potential Dogs if EPAC's growth in that area is below the industry rate of 11.79%. When a business unit is in a market growing at nearly 12% but the company is only achieving 1.0% overall organic growth, it strongly implies that the specific product lines serving that market have a low market share and are not capturing the market expansion.
You should focus your attention on these specific areas for potential strategic action:
- IT&S Service revenue organic decline of 7.4% in Q4 2025.
- IT&S segment organic sales decline of 2.2% in Q4 2025.
- Weakness in the EMEA region, which accounts for 40% of IT&S regional sales.
- Products in the soft industrial sector lagging the industry rate of 11.79%.
Expensive turn-around plans are generally ill-advised for these units; the capital tied up in inventory, working capital, and overhead for a Dog could be better deployed into the Stars or Question Marks showing higher potential. Finance: draft 13-week cash view by Friday.
Enerpac Tool Group Corp. (EPAC) - BCG Matrix: Question Marks
The Question Marks quadrant represents business units operating in high-growth markets but currently holding a low market share. For Enerpac Tool Group Corp. (EPAC), these areas require significant cash investment to capture market share or risk becoming Dogs.
The Heavy Lifting Technology (HLT) business has been recently bolstered by the DTA acquisition. The transaction was valued at €24 million plus potential earn-out tied to a three-year performance period. For the fiscal year 2025, DTA was projected to generate approximately €20 million in revenue.
The DTA acquisition integration requires continued investment to realize its potential through cross-selling and market share gains. The initial expectation for fiscal 2025 was a neutral effect on adjusted earnings per share, excluding one-time transaction costs and before synergy accounting.
The overall Industrial Tools & Services (IT&S) segment, despite being the main segment, demonstrated low organic growth in fiscal 2025. The segment's total net sales increased by 4.3%, largely due to the DTA acquisition.
The core performance of the IT&S segment is detailed below:
| Metric | Value/Rate |
| IT&S Segment Organic Growth (Fiscal 2025) | 0.5% |
| IT&S Organic Product Revenue Growth (Fiscal 2025) | 0.3% |
| IT&S Organic Service Revenue Growth (Fiscal 2025) | 1.3% |
| Overall Company Organic Growth (Fiscal 2025) | 1.0% |
The company is making capital-intensive growth bets through investments in infrastructure. These investments are necessary to support future growth potential, which is the core thesis for managing Question Marks.
- Capital expenditures for the full fiscal year 2025 totaled $19.3 million.
- This represented an increase of $7.9 million compared to the prior year's capital expenditures.
- The primary driver for the increased capital spend was the build-out of the new global headquarters in downtown Milwaukee.
- The relocation to the new Milwaukee headquarters was completed during the third quarter of fiscal 2025.
- The R&D organization is seeing impact from the investment in the new and expanded Innovation Lab.
The overall company achieved record revenue of $616.9 million in fiscal 2025.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.